Opendata, web and dolomites

denovoSkin SIGNED

Personalized, bio-engineered skin grafts for the permanent treatment of skin defects

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 denovoSkin project word cloud

Explore the words cloud of the denovoSkin project. It provides you a very rough idea of what is the project "denovoSkin" about.

classified    projected    patient    de    sme    logistics    invested    transplantation    human    autografting    17    off    corrective    atmp    health    last    starting    plan    financial    solving    therapy    market    minimal    standard    assuring    clinical    autologous    fda    orphan    quantities    burns    trade    economic    risking    surgeries    life    excision    designation    investment    bio    interventions    50m    structure    considerably    patented    considerable    stamp    intense    medical    follow    surgical    sound    debilitating    global    personalized    biopsy    treatment    care    patients    graft    every    sized    issue    function    homecare    impair    site    disfiguring    reduce    savings    rehabilitation    intervention    hence    granted    16    fits    suffer    leads    entire    drug    worldwide    swissmedic    painful    epidermal    wounds    instrument    burden    quality    permanent    scars    skin    leaves    fast    world    restore    psychosocial    performance    deployment    movement    donor    avoids    57m    automate    denovoskin    optimal    scarrring    shortage    engineered    5m    dermo    defects    ema    significantly    outstanding   

Project "denovoSkin" data sheet

The following table provides information about the project.

Coordinator
CUTISS AG 

Organization address
address: WEINBERGSTRASSE 35 WYSS TRANSLATIONAL CENTER ZURICH DENOVOS
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://cutiss.swiss/
 Total cost 3˙571˙237 €
 EC max contribution 2˙499˙866 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CUTISS AG CH (ZURICH) coordinator 2˙499˙866.00

Map

 Project objective

Every year in the world, more than 50M patients suffer from skin defects (e.g. burns, excision, etc.) and need surgical intervention to restore skin function. Standard of care, skin autografting, very often leaves these patients with scars. Scars are permanent and disfiguring, and can also be painful and highly debilitating. Indeed, they may also impair movement and growth, and require several follow-up surgeries, intense homecare and psychosocial rehabilitation. Hence, scars significantly affect patient’s quality of life, along with the economic burden for the health-care system. Furthermore, in the case of large wounds, donor site shortage represents a real clinical issue.

denovoSkin™ is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin™ leads to minimal scarrring after transplantation. Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings in terms of costs. denovoSkin™ is also granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA.

So far, more than €17.5M have been invested over the last 16 years of research into the development and the clinical testing of denovoSkin™. To have denovoSkin™ fully projected at a European and global level we need a further investment of €3.57M to automate its production, de-risking the entire denovoSkin™ project by assuring a real delivery to patients worldwide while providing optimal logistics and quality of product.

The proposed work in Phase 2 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of denovoSkin™ and its market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DENOVOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DENOVOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Path Feel (2019)

Insoles for Neuropathy and Balance Issues

Read More  

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More